Notitia Biotechnologies

Rutgers University

Notitia Biotechnologiesis a microbiome-targeted biotherapeutic company. It uses a revolutionary Foundation Guild platform that leverages data from the gut microbiome to develop therapies and products focused on the ecological restoration of the gut ecosystem. Notitia uses a proprietary reference-free predictive analysis to discover the novel and fundamental players in the gut microbiome and guide its product development pipeline. Traditional and competing technologies rely on reference-dependent taxon-based analyses, which discard large portions of sequence data and ignores novel players in the microbiome.


Jeffrey Zhao is the co-founder and CEO of Notitia Biotechnologies. Jeffrey is an entrepreneur with experience in health & wellness startups. He has previously managed marketing operations in multiple international markets and skilled in performing wet and dry-lab benchwork in microbiome-related research.

Dr. Liping Zhao, Scientific Cofounder and President, is the Eveleigh-Fenton Chair of Applied Microbiology from Rutgers University. He is the world’s leader in microbiome and the discoverer of the Foundation Guildâ„¢ concept. His previous works featured in the prestigious Science journal.

Greg Stokes, Business Advisor, has over 29 years of experience in sales, marketing, and business development in the pharmaceutical industry. He has cofounded multiple pharma startups, all resulted in successful 3x to 10x return for investors and shareholders.

Tim Lee, Business and Research Analyst, is an analytics professional with experience leading data science initiatives for business, marketing, and customer success analytics. He has a masters in Business Analytics from the University of Utah.

Michelle Nishiguchi, Associate Research Scientist, is a scientist with proven experience in research and developing laboratory protocols. She was previously involved in projects such as bacteriophage isolation for eliminating antibiotic-resistant bacteria, vaccine development for Siadenovirus, and data integrity for cancer research.